Augustine Therapeutics will be participating to the BIO-EUROPE conference in Leipzig, Germany from 24th October to 26th October 2022.

We will be sharing the latest development on our lead program targeting HDAC6 aiming at preventing and reversing axonal degeneration, restoring muscle reinnervation in neuromuscular disorders such as Charcot-Marie-Tooth disease and other peripheral neuropathies.

Sylvain Celanire, CEO, and Paul Leijten, Business Development Adviser, will be available for one-on-one meetings throughout the 3-day conference.